Cure8 research brief
Researchers used laboratory mouse and cell models to show that total glucosides of paeony (TGP) may reduce inflammation linked to ulcerative colitis and identified molecular pathways (COX‑2/arachidonic acid, NF‑κB, MAPK, AKT) that TGP appears to affect.
That helps explain how TGP could work and guides further research toward potential treatments.
Researchers studying IBD therapeutics, clinicians interested in emerging preclinical treatments, and patients following research on botanical or alternative therapies for ulcerative colitis.
This paper reports an integrated network-pharmacology and untargeted metabolomics study of total glucosides of paeony (TGP) in laboratory models of ulcerative colitis (DSS-treated mice and LPS-stimulated intestinal epithelial cells).
The authors measured disease activity, colon length, histology, metabolite profiles (LC–MS/MS), and molecular markers (RT‑PCR, ELISA, Western blot, flow cytometry) to explore mechanisms. TGP treatment was associated with lower DAI scores, less colon shortening, and improved histopathology in the mouse colitis model.
Metabolomics and network analyses highlighted the arachidonic acid/COX-2 pathway and reduced expression of inflammatory mediators (IL‑6, TNF‑α, COX‑2) plus decreased activation of AKT, p38 MAPK, and NF‑κB signaling. High-dose TGP lowered the splenic Th17/Treg ratio in DSS mice.
This article provides mechanistic laboratory data suggesting anti-inflammatory effects of TGP in preclinical UC models. It does not provide clinical trial evidence of benefit in people with UC, nor safety data in patients.
If you want to read further, look for clinical studies or randomized trials of TGP in ulcerative colitis to see whether these preclinical signals translate to patient outcomes.
This report is based on preclinical experiments (DSS mouse model and LPS‑stimulated cell line) and integrated metabolomics/network analyses; it does not report human clinical trial results. Findings identify candidate pathways and warrant further study, including safety and efficacy testing in humans.
Review the original publication for the complete reporting, methods, and context.
This Cure8 brief is based on source text from the linked article. Cure8 is informational only and is not a substitute for professional medical advice, diagnosis, or treatment.
Long-term safety data on biologics and thiopurines are important for people with ulcerative colitis because they help patients and clinicians weigh risks (including malignancies and pregnancy-related outcomes) when...
The study points to three bile-acid–related genes that may be linked to inflammation in ulcerative colitis and could serve as biomarkers or targets for future research into disease mechanisms and patient stratification.
Vedolizumab blood levels can vary with disease activity; a model that links intestinal α4β7 expression to drug exposure helps explain why some patients have lower drug levels and may need different dosing. This could...
